NEWTOWN, Pa., Sept. 22, 2021 (GLOBE NEWSWIRE) — Helius Medical Applied sciences, Inc. (Nasdaq: HSDT) (“Helius” or the “Firm”), a neurotech firm targeted on neurological wellness, immediately introduced that Dane C. Andreeff, President and Chief Govt Officer, will current on the Benzinga Healthcare Small Cap Convention as follows:
The presentation will probably be webcast dwell on the aforementioned time, and archived for 30 days thereafter, through the Firm’s web site at www.heliusmedical.com, underneath the Traders Relations part.
About Helius Medical Applied sciences, Inc.
Helius Medical Applied sciences is a neurotech firm targeted on neurological wellness. The Firm’s goal is to develop, license and purchase distinctive and non-invasive platform applied sciences that amplify the mind’s skill to heal itself. The Firm’s first industrial product is the Moveable Neuromodulation Stimulator (PoNS™). For extra data, go to www.heliusmedical.com.
Concerning the PoNS™ System and PoNS Therapy™
The Moveable Neuromodulation Stimulator (PoNS™) is an progressive non-surgical machine, inclusive of a controller and mouthpiece, which delivers electrical stimulation to the floor of the tongue to supply remedy of gait deficit. The PoNS machine is indicated to be used in america as a brief time period remedy of gait deficit attributable to mild-to-moderate signs from a number of sclerosis (“MS”) and is for use as an adjunct to a supervised therapeutic train program in sufferers 22 years of age and over by prescription solely. PoNS is permitted on the market in Canada for 2 indications: PoNS is permitted as brief time period remedy (14 weeks) of continual stability deficit attributable to mild-to-moderate traumatic mind damage and is for use at the side of bodily remedy. PoNS is permitted to be used as a brief time period remedy (14 weeks) of gait deficit attributable to delicate and reasonable signs from A number of Sclerosis (MS) and is for use at the side of bodily remedy. The PoNS™ is an investigational medical machine within the Australia (“AUS”) and is at the moment underneath premarket evaluate by the AUS Therapeutic Items Administration.
Investor Relations Contact:
Lisa M. Wilson, In-Website Communications, Inc.